Piramal Pharma Solutions, a CDMO, part of Piramal Pharma Ltd., opened its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland.

The expansion further enhances the site’s capacity by approximately seventy to eighty percent, enabling scale-up of commercial ADC manufacturing batches. The capacity expansion features two new ADC manufacturing suites specifically designed to complement the existing three. The £45 million investment was financed by a combination of Scottish Enterprise government grant, bank loan, customer co-investment, and internal accruals.

The site’s enhanced ability to deliver the full life cycle of ADC development and manufacturing includes ADCelerate, the company’s branded service for the rapid early-stage development of ADC drugs. The integrated offering combines the development of the monoclonal antibody (mAb), linker/payload, conjugation, and sterile fill/finish into a single integrated program across four global Piramal sites, including Grangemouth. The approach aims to simplify development and manufacturing and speed up processes.

The site expansion also includes a dedicated customer experience center for clients, along with new quality control laboratories, warehousing, office space, and supporting utilities. The building, which utilized modular construction technology to expedite its completion, has been designed to accommodate further expansion. Potential future enhancements may include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes.

Peter DeYoung, CEO, Piramal Pharma Solutions, said, “The global ADC market is growing strongly and so is the pipeline at Grangemouth, necessitating additional capacity to meet customer demand. This expansion allows us to cater to further growth and take on future projects. We see the market gravitating towards large and commercial scale manufacturing, which the new facility is well equipped to address. We’ve now doubled our ADC production capacity, strengthening our ability to service customers throughout the entire drug lifecycle.”